Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients

• Status: Terminated
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this pilot-trial is the feasibility of a large randomized, placebo controlled, doubleblind clinical trial to investigate the use of methylphenidate, rivastigmine or haloperidol in hypoactive ICU-delirium. In addition we will compare duration of delirium, severity of delirium, length of ICU/hospital stay and side effects between the different interventions.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UMC Utrecht
• Treatments: Haloperidol; Haloperidol decanoate; Methylphenidate; Rivastigmine

Criteria

Inclusion Criteria:

• Older than 18 years

• Diagnosed as hypoactive delirium

• Informed consent given

Exclusion Criteria:

• Pregnancy

• Epilepsy

• M. Parkinson

• Lewy-body dementia

• Prolonged QT-time

• Known allergy to the medicinals used

• Renal replacement therapy

• Hepatic encephalopathy

• Hyperthyroid

• Glaucoma

• Previous suicide attempts

• Syndrome of Gilles de la Tourette

• Patients which cannot receive the medication oral or through a nasogastric tube